| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6011 | 2012 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 2973 | 2009 |
| A variant associated with nicotine dependence, lung cancer and peripheral arterial disease TE Thorgeirsson, F Geller, P Sulem, T Rafnar, A Wiste, KP Magnusson, ... Nature 452 (7187), 638-642, 2008 | 1667 | 2008 |
| Sequence variants at the TERT-CLPTM1L locus associate with many cancer types T Rafnar, P Sulem, SN Stacey, F Geller, J Gudmundsson, A Sigurdsson, ... Nature genetics 41 (2), 221-227, 2009 | 703 | 2009 |
| Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ... Journal of clinical oncology 25 (19), 2747-2754, 2007 | 667 | 2007 |
| Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head … R Hitt, A López-Pousa, J Martínez-Trufero, V Escrig, J Carles, A Rizo, ... Journal of Clinical Oncology 23 (34), 8636-8645, 2005 | 588 | 2005 |
| Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients R Rosell, KD Danenberg, V Alberola, G Bepler, JJ Sanchez, C Camps, ... Clinical Cancer Research 10 (4), 1318-1325, 2004 | 553 | 2004 |
| Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ... The lancet oncology 16 (8), 897-907, 2015 | 507 | 2015 |
| The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy AG Ramírez-Labrada, D Isla, A Artal, M Arias, A Rezusta, J Pardo, ... Trends in cancer 6 (2), 86-97, 2020 | 165 | 2020 |
| Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway R Rosell, M Taron, N Reguart, D Isla, T Moran Clinical cancer research 12 (24), 7222-7231, 2006 | 133 | 2006 |
